EARLY GRAPHICAL APPEARANCE OF RADIATION PNEUMONITIS CORRELATES WITH THE SEVERITY OF RADIATION PNEUMONITIS AFTER STEREOTACTIC BODY RADIOTHERAPY (SBRT) IN PATIENTS WITH LUNG TUMORS

被引:47
|
作者
Takeda, Atsuya [2 ,4 ]
Ohashi, Toshio [2 ]
Kunieda, Etsuo [1 ]
Enomoto, Tatsuji [3 ]
Sanuki, Naoko [4 ]
Takeda, Toshiaki [2 ]
Shigematsu, Naoyuki
机构
[1] Keio Univ, Dept Radiol, Shinjuku Ku, Tokyo 1608582, Japan
[2] Tokyo Metropolitan Hiroo Gen Hosp, Dept Radiol, Tokyo, Japan
[3] Tokyo Metropolitan Hiroo Gen Hosp, Dept Respirol, Tokyo, Japan
[4] Ofuna Chuo Hosp, Dept Radiol, Kanagawa, Japan
关键词
Stereotactic body radiotherapy; Radiation pneumonitis; Lung cancer; PULMONARY-FIBROSIS; DOSIMETRIC FACTORS; STEROID-THERAPY; CANCER; INJURY; PREDICTION; CT; FRACTIONS; VOLUME; GY;
D O I
10.1016/j.ijrobp.2009.06.001
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To investigate factors associated with Grade >= 3 radiation pneumonitis (RP) in patients with lung tumors treated with stereotactic body radiotherapy (SBRT). Methods and Materials: We retrospectively analyzed 128 patients with 133 lung tumors treated with SBRT. RP was graded according to the Common Terminology Criteria for Adverse Events version 3.0. Univariate analyses were used to identify predictive factors for RP. Results: The median follow-up period after SBRT was 12 months (range, 5-45 months). Incidences of Grades 0, 1, 2, and 3 RP were 27%, 52%, 16%, and 5%, respectively. No patients suffered Grade 4 or 5 RP. For all patients with Grade 2 or 3, symptoms occurred either simultaneously with or subsequent to graphical appearances. The latent period was the only significant factor associated with Grade >= 3 RP (p < 0.01). A latent period of 1 or 2 months indicated a 40% (6/15) risk for Grade 3. However, the risk for Grade 3 was 1.2% (1/82) 3 months after SBRT. No pretreatment clinical or dosimetric factors were significantly associated with Grade >= 3 RP. However, 4 of 7 patients with Grade 3 RP had severe pulmonary comorbidities. Conclusion: Only the latency period was a significant factor in the development of RP. No pretreatment clinical or dosimetric factors were significantly associated with Grade >= 3 RP. Patients, especially those with severe pulmonary comorbidities, should be carefully observed for the graphical appearance of RP within a few months during the follow-up period after SBRT. (C) 2010 Elsevier Inc.
引用
收藏
页码:685 / 690
页数:6
相关论文
共 50 条
  • [1] Complication probability for radiation pneumonitis (RP) after stereotactic body radiotherapy (SBRT)
    Grimm, Jimm
    Palma, David
    Senan, Suresh
    Xue, Jinyu
    [J]. JOURNAL OF RADIOSURGERY AND SBRT, 2013, 2 (02): : 99 - 104
  • [2] Tumor Location Correlates with Radiation Pneumonitis after Stereotactic Body Radiation Therapy (SBRT) for Primary and Oligometastatic Lesions of the Lung
    Bhirud, A. R.
    Dunlap, N.
    Sheng, K.
    Read, P.
    Larner, J.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2011, 81 (02): : S626 - S626
  • [3] Risk Factors for Symptomatic Radiation Pneumonitis after Stereotactic Body Radiotherapy (SBRT) for Early-Stage Lung Cancer
    Kita, N.
    Tomita, N.
    Takaoka, T.
    Mekata, Y.
    Okazaki, D.
    Niwa, M.
    Torii, A.
    Takano, S.
    Hiwatashi, A.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2023, 117 (02): : E30 - E30
  • [4] Clarithromycin mitigates radiation pneumonitis in patients with lung cancer treated with stereotactic body radiotherapy
    Takeda, Atsuya
    Tsurugai, Yuichiro
    Sanuki, Naoko
    Enomoto, Tatsuji
    Shinkai, Masaharu
    Mizuno, Tomikazu
    Aoki, Yousuke
    Oku, Yohei
    Akiba, Takeshi
    Hara, Yu
    Kunieda, Etsuo
    [J]. JOURNAL OF THORACIC DISEASE, 2018, 10 (01) : 247 - 261
  • [5] Stereotactic body radiotherapy for lung tumors in patients with subclinical interstitial lung disease: The potential risk of extensive radiation pneumonitis
    Yamaguchi, Shinsaku
    Ohguri, Takayuki
    Ide, Satoru
    Aoki, Takatoshi
    Imada, Hajime
    Yahara, Katsuya
    Narisada, Hiroyuki
    Korogi, Yukunori
    [J]. LUNG CANCER, 2013, 82 (02) : 260 - 265
  • [6] Bayesian Network Representation of Radiation Pneumonitis Onset After Hypofractionated Stereotactic Body Radiation Therapy (SBRT) for Lung Cancer
    Lee, S.
    Ybarra, N.
    Jeyaseelan, K.
    Faria, S.
    Kopek, N.
    El Naqa, I.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2015, 93 (03): : S54 - S55
  • [7] Impact of Pretreatment Interstitial Lung Disease on Radiation Pneumonitis and Survival in Patients Treated With Lung Stereotactic Body Radiation Therapy (SBRT)
    Glick, D.
    Lyen, S.
    Le, L.
    Lindsay, P. E.
    Wong, O.
    Bezjak, A.
    Brade, A. M.
    Cho, J.
    Hope, A. J.
    Sun, A.
    Shapera, S.
    Kandel, S.
    Giuliani, M. E.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2016, 96 (02): : E431 - E431
  • [8] Impact of Pretreatment Interstitial Lung Disease on Radiation Pneumonitis and Survival in Patients Treated With Lung Stereotactic Body Radiation Therapy (SBRT)
    Glick, Daniel
    Lyen, Stephen
    Kandel, Sonja
    Shapera, Shane
    Le, Lisa W.
    Lindsay, Patricia
    Wong, Olive
    Bezjak, Andrea
    Brade, Anthony
    Cho, B. C. John
    Hope, Andrew
    Sun, Alexander
    Giuliani, Meredith
    [J]. CLINICAL LUNG CANCER, 2018, 19 (02) : E219 - E226
  • [9] Radiation pneumonitis after stereotactic radiation therapy for lung cancer
    Yamashita, Hideomi
    Takahashi, Wataru
    Haga, Akihiro
    Nakagawa, Keiichi
    [J]. WORLD JOURNAL OF RADIOLOGY, 2014, 6 (09): : 708 - 715
  • [10] Risk Factors of Radiation Pneumonitis After Stereotactic Ablative Body Radiation Therapy for Primary and Metastatic Lung Tumors
    Kim, K.
    Lee, C. G.
    Cho, J. H.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2016, 96 (02): : E461 - E462